help button home button Endocrine Society Endocrinology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Liu, J. L.
Right arrow Articles by Patel, Y. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Liu, J. L.
Right arrow Articles by Patel, Y. C.

Endocrinology, Vol 136, 2389-2396, Copyright © 1995 by Endocrine Society


ARTICLES

Glucocorticoids inhibit somatostatin gene expression through accelerated degradation of somatostatin messenger ribonucleic acid in human thyroid medullary carcinoma (TT) cells

JL Liu and YC Patel
Fraser Laboratories, Department of Medicine, McGill University Royal Victoria Hospital, Quebec, Canada.

We previously reported that dexamethasone (DEX) induces dose-dependent biphasic effects on steady state somatostatin (SS) messenger RNA (mRNA) levels in normal rat islet and islet SS-producing tumor cells (1027B2), characterized by stimulation at low doses and marked inhibition at high doses. The stimulatory effect is transcriptionally mediated, whereas the molecular mechanism underlying DEX-induced suppression of SS mRNA levels is unknown. In the present study, we investigated these mechanisms in human thyroid medullary carcinoma (TT) cells, which exhibit only inhibition of SS mRNA with DEX. Cultured TT cells synthesized and secreted large quantities of SS-like immunoreactivity (content, 90 ng/10(6) cells; release, 18 ng/10(6) cells/24h). DEX produced a dose-dependent reduction of both SS-like immunoreactivity secretion and SS mRNA levels, with a maximum inhibition of 60% at 10(- 6) M at 48 h. In time-course studies, DEX inhibition of SS function occurred after a lag period of about 12 h, suggesting a posttranscriptional mechanism. To exclude a transcriptional effect of DEX on the SS gene, chloramphenicol acetyltransferase (CAT) activity was determined in TT cells acutely transfected with SS promoter (-750 base pairs) ligated to the receptor CAT gene. No inhibition of CAT activity occurred with DEX (10(-6) M) for 48 h. Furthermore, DEX did not influence the rate of SS gene transcription determined by nuclear run-on assay compared to approximately 2-fold stimulation by cAMP. Actinomycin D (inhibitor of mRNA synthesis) reduced the size of the SS mRNA transcript and rendered it resistant to DEX-induced degradation when coincubated with DEX, but not when it was added after a delay of 12 h, indicating that DEX destabilizes SS mRNA by an active process requiring ongoing gene transcription. Cycloheximide (inhibitor of protein synthesis) reduced SS mRNA levels to the same level as DEX, suggesting that the two agents promote SS mRNA degradation through a common pathway. We conclude that glucocorticoids inhibit steady state SS mRNA levels in TT cells. This effect is not mediated through direct transcriptional inhibition of the SS gene. It requires transcription of another gene(s) whose product(s) accelerates SS mRNA degradation.


This article has been cited by other articles:


Home page
J. Clin. Endocrinol. Metab.Home page
M. C. Zatelli, F. Tagliati, J. E. Taylor, R. Rossi, M. D. Culler, and E. C. degli Uberti
Somatostatin Receptor Subtypes 2 and 5 Differentially Affect Proliferation in Vitro of the Human Medullary Thyroid Carcinoma Cell Line TT
J. Clin. Endocrinol. Metab., May 1, 2001; 86(5): 2161 - 2169.
[Abstract] [Full Text]


Home page
Mol. Endocrinol.Home page
J.-L. Liu, A. Grinberg, H. Westphal, B. Sauer, D. Accili, M. Karas, and D. LeRoith
Insulin-Like Growth Factor-I Affects Perinatal Lethality and Postnatal Development in a Gene Dosage-Dependent Manner: Manipulation Using the Cre/loxP System in Transgenic Mice
Mol. Endocrinol., September 1, 1998; 12(9): 1452 - 1462.
[Abstract] [Full Text]


Home page
Am. J. Physiol. Renal Physiol.Home page
M. A. Turman and C. A. Apple
Human proximal tubular epithelial cells express somatostatin: regulation by growth factors and cAMP
Am J Physiol Renal Physiol, June 1, 1998; 274(6): F1095 - F1101.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
J.-L. Liu, V. A. Blakesley, J. S. Gutkind, and D. LeRoith
The Constitutively Active Mutant Galpha 13 Transforms Mouse Fibroblast Cells Deficient in Insulin-like Growth Factor-I Receptor
J. Biol. Chem., November 21, 1997; 272(47): 29438 - 29441.
[Abstract] [Full Text] [PDF]


Home page
EndocrinologyHome page
M. Quintela, R. M. SenarIs, and C. Dieguez
Transforming Growth Factor-{beta}s Inhibit Somatostatin Messenger Ribonucleic Acid Levels and Somatostatin Secretion in Hypothalamic Cells in Culture
Endocrinology, October 1, 1997; 138(10): 4401 - 4409.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 1995 by The Endocrine Society